Completed PHASE2 INTERVENTIONAL 1-arm NCT01091103

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

A Study Of Continuous Oral Dosing Of A Novel Antiandrogen Mdv3100, In Castration-resistant Bone Metastatic Prostate Cancer Patients Evaluating The Tumor Micro-enviroment

Sponsor: Astellas Pharma Inc

Conditions Metastatic Progressive Castration-resistant Prostate Cancer

Interventions Enzalutamide

Updated 8 times since 2017 Last updated: Oct 19, 2018 Started: Feb 18, 2010 Primary completion: Feb 29, 2012 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Progressive Castration-resistant Prostate Cancer and is currently completed. Astellas Pharma Inc leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Oct 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States